Birth size is a marker of susceptibility to breast cancer later in lifeSeptember 30, 2008Birth size, and in particular birth length, correlates with subsequent risk of breast cancer in adulthood, according to a new study published in PLoS Medicine by researchers at the London School of Hygiene and Tropical Medicine. Associations between birth size, perhaps as a marker of the pre-natal environment, and subsequent breast cancer risk have been identified before, but the findings from epidemiological studies have been inconsistent. In the new study, led by Isabel dos Santos Silva (Professor of Epidemiology), the researchers re-analysed data from published and unpublished studies to obtain more precise estimates of the extent to which birth size affects the risk of breast cancer later in life and to investigate whether they could be explained by associations with other risk factors. They examined 32 studies, comprising 22,058 cases of breast cancer among a total of more than 600,000 women, most of whom lived in developed countries. They found that birth weight was positively associated with breast cancer risk in studies where information on birth size was based on birth records (although not in those based on adult self-reports, which tend to be less accurate). Analyses of women with data from birth records showed that a 0.5 kg increment in birth weight was associated with an estimated 7% increase in the risk of breast cancer. Birth length and head circumference were also positively associated with breast cancer risk when studies with data from birth records were analyzed. Of the three birth size measures examined, birth length appeared to be the strongest independent predictor of risk. The estimated magnitude of the birth size association with breast cancer risk was not affected when the effects of established breast cancer risk factors were accounted for. Isabel dos Santos Silva commented: 'Our study indicates that birth size is a marker of susceptibility to breast cancer in adulthood, at least in developed countries. The birth size - breast cancer association appeared to be largely independent of known risk factors. Little is known on how the pre-natal environment may affect breast cancer risk later in life. Further research is needed to unravel the biological mechanisms underlying the birth size - breast cancer association'. In an expert commentary, Pagona Lagiou and Dimitrios Trichopoulos of Harvard University School of Public Health, who were not involved in the study, say that the new study provides "the strongest evidence yet that birth size is a critical determinant of breast cancer risk in adult life." Citation: dos Santos Silva I, De Stavola B, McCormack V, Collaborative Group on Pre-Natal Risk Factors and Subsequent Risk of Breast Cancer (2008) Birth size and breast cancer risk: Re-analysis of individual participant data from 32 studies. PLoS Med 5(9): e193. doi:10.1371/journal.pmed.0050193 http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050193 Public Library of Science |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||